The U.S. ECMO machine market size was exhibited at USD 80.95 million in 2023 and is projected to hit around USD 137.23 million by 2033, growing at a CAGR of 5.42% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 85.34 Million |
Market Size by 2033 | USD 137.23 Million |
Growth Rate From 2024 to 2033 | CAGR of 5.42% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Component, Modality, Patient Type, Application |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Country scope | U.S. |
Key Companies Profiled | Inspira; Abbott; Terumo Cardiovascular Systems Corporation CytoSorbents Corporation; Cyberonics, Inc; OriGenGOHIBIC™; Agilent Technologies; Soma Tech Intl; Mott Corporation |
This growth can be attributed to the rising incidence of cardiopulmonary and respiratory diseases along with a rising number of patients suffering from chronic obstructive pulmonary disease (COPD). Furthermore, technological advances in extracorporeal membrane oxygenation (ECMO) machines increase its adoption among healthcare professionals, fueling market growth.
The U.S. ECMO machine accounted for a 26.0% share in the global extracorporeal membrane oxygenation machine market. The rise in respiratory diseases is expected to boost the market growth. Several respiratory diseases affect individuals, such as bronchiectasis, hypersensitivity pneumonitis, lung fibrosis, asthma, Chronic Obstructive Pulmonary Disease (COPD), and lung cancer. COPD is known to be the third most common cause of death in the United States, following cancer and cardiac diseases. According to the American Lung Association, over 11 million people are diagnosed with COPD in the US every year. The high incidence of COPD has caused a greater demand for ECMO in the market than currently available.
The ECMO market has experienced significant growth due to the rapid integration of ECMO machines in healthcare facilities and the implementation of awareness initiatives. Technological progressions like oxygenators, hollow pumps, and heparin-coated cannula have broadened the scope of ECMO applications in surgical procedures. Moreover, the evolution of smaller, portable ECMO machines has enhanced their versatility and usage. Introducing portable adapters and compact ECMO machine systems has simplified the transport of critically ill patients, fueling market expansion.
Moreover, the rising geriatric population, along with the growing incidence of coronary heart disease, is bolstering the adoption of ECMO machines. As per the Population Statistics Bureau 2022, the number of Americans 65 years of age and older is expected to increase from 58 million to 82 million by 2050, accounting for a 47% increase. This demographic shift, along with the strong association of coronary heart disease with age, is one of the leading causes of death worldwide and is driving the need for advanced life support technologies like ECMO machines. However, potential challenges such as infections, technical failures, bleeding, and the prohibitive cost of treatment may pose barriers to the market's growth.
Oxygenators dominated the market with a share of 37% in 2023 and are expected to remain dominant over the forecast period. The high prevalence of lung diseases and the growing popularity of ECMO machines drive the segment’s growth. According to CDC statistics, 4.6% of US adults have been diagnosed with COPD, emphysema, or chronic bronchitis in 2022. Such respiratory disorders further lead to increased demand for oxygenators in the market.
The blood pump component is expected to grow significantly from 2024 to 2033. The significant expansion of this segment is mainly due to its extensive utilization in ECMO processes and the presence of multiple pump varieties like roller, impeller, and centrifugal pumps. These pumps are applied in different ECMO procedures according to their specific needs.
Veno-arterial ECMO modality held the largest share in 2023 and is expected to grow at the fastest CAGR over the forecast period, owing to an increased need for cardiac support in cardiac arrest incidences. Moreover, the veno-arterial ECMO machine is used to treat patients suffering from pulmonary embolism and pulmonary hypertension, especially in the case of acute decompensation. This modality performs the dual function of providing hemodynamic support and gaseous exchange. It pumps the blood toward the arterial side. VA-ECMO configuration helps pump the patient’s lungs, heart, and blood through the ECMO circuit.
The veno-venous segment is expected to witness growth from 2024 to 2033. The increasing incidence of chronic obstructive pulmonary disease (COPD) drives this market segment significantly. The veno-venous ECMO supports the lungs and allows blood oxygenation for all the time needed for the failing lung to recover.
The adult patient segment dominated the market with a share of 60.0% in 2023. The high prevalence of cardiac and respiratory conditions in the geriatric population accelerates the growth of this segment. Recent CDC data from 2021 reveals that a significant percentage of adults in different age groups are susceptible to cardiac diseases in the U.S. Specifically, the data shows that around 1.0% of adults aged 18 to 44, 3.6% of adults aged 45 to 54, 9.0% of adults aged 55 to 64, 14.3% of adults aged 65 to 74, and 24.2% of adults aged 75 and over are affected, thereby contributing to the market growth.
Neonates’ patients' segment is accelerating with a significant CAGR from 2024 to 2033 owing to high dominance of heart diseases within the neonatal population. As per CDC statistics, approximately 16,800 babies are born each year in the United States with a ventricular septal defect. Similarly, 40,000 babies are born with congenital heart diseases annually in the U.S. These cardiac disorders boost the demand for ECMO, thereby fueling the segment’s growth.
Respiratory applications dominated the market with a 49.0% share in 2023. The significance of ECMO and the high prevalence of respiratory conditions will likely enhance the segment’s growth. ECMO serves as pulmonary support to perform efficient respiratory function in patients. This feature increases its demand and thereby boosts market growth.
Extracorporeal cardiopulmonary resuscitation (ECPR) is projected to grow at the fastest CAGR of 5.8% over the forecast period. An increasing number of cardiac arrests is driving the growth trajectory of this segment. ECPR is considered rescue therapy for patients suffering from in-hospital cardiac arrest as well as out-of-hospital cardiac arrest. Such applications of ECPR are likely to expand the growth opportunities of ECPR in the forecast period.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. ECMO machine market
Component
Modality
Patient Type
Application
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Component
1.2.2. Modality
1.2.3. Patient Type
1.2.4. Application
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Italy
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Component
2.2.2. Modality
2.2.3. Patient Type
2.2.4. Application
2.3. Competitive Insights
Chapter 3. U.S. Extracorporeal Membrane Oxygenation Machine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.3. Market Driver Analysis
3.4. Market Restraint Analysis
3.5. Industry Analysis - Porter’s Five Forces
3.5.1. Supplier power
3.5.2. Buyer power
3.5.3. Substitution threat
3.5.4. Threat of new entrant
3.5.5. Competitive rivalry
3.6. PESTEL Analysis
3.6.1. Political landscape
3.6.2. Technological landscape
3.6.3. Economic Landscape
Chapter 4. U.S. Extracorporeal Membrane Oxygenation Machine Market Component Estimates & Trend Analysis
4.1. U.S. Extracorporeal Membrane Oxygenation Machine Market Component Model Dashboard
4.2. U.S. Extracorporeal Membrane Oxygenation Machine Market Component Movement Analysis
4.3. Pumps
4.3.1. Pumps Market Revenue Estimates and Forecasts, 2021 - 2033
4.4. Oxygenator
4.4.1. Oxygenator Market Revenue Estimates and Forecasts, 2021 - 2033
4.5. Controllers
4.5.1. Controllers Market Revenue Estimates and Forecasts, 2021 - 2033
4.6. Cannula
4.6.1. Cannula Market Revenue Estimates and Forecasts, 2021 - 2033
4.7. Accessories
4.7.1. Accessories Market Revenue Estimates and Forecasts, 2021 - 2033
Chapter 5. U.S. Extracorporeal Membrane Oxygenation Machine Market Modality Estimates & Trend Analysis
5.1. U.S. Extracorporeal Membrane Oxygenation Machine Market Modality Model Dashboard
5.2. U.S. Extracorporeal Membrane Oxygenation Machine Market Modality Movement Analysis
5.3. Veno-Arterial
5.3.1. Veno-Arterial Market Revenue Estimates and Forecasts, 2021 - 2033
5.4. Veno-Venous
5.4.1. Veno-Venous Market Revenue Estimates and Forecasts, 2021 - 2033
5.5. Arterio-Venous.
5.5.1. Arterio-Venous Market Revenue Estimates and Forecasts, 2021 - 2033
Chapter 6. U.S. Extracorporeal Membrane Oxygenation Machine Market Patient Type & Trend Analysis
6.1. U.S. Extracorporeal Membrane Oxygenation Machine Market Patient Type Model Dashboard
6.2. U.S. Extracorporeal Membrane Oxygenation Machine Market Patient Type Movement Analysis
6.3. Neonates
6.3.1. Neonates Market Revenue Estimates and Forecasts, 2021 - 2033
6.4. Pediatric
6.4.1. Pediatric Market Revenue Estimates and Forecasts, 2021 - 2033
6.4.2. Adult Market Revenue Estimates and Forecasts, 2021 - 2033
Chapter 7. U.S. Extracorporeal Membrane Oxygenation Machine Market Application & Trend Analysis
7.1. U.S. Extracorporeal Membrane Oxygenation Machine Market Application Model Dashboard
7.2. U.S. Extracorporeal Membrane Oxygenation Machine Market Application Movement Analysis
7.3. Respiratory
7.3.1. Respiratory Market Revenue Estimates and Forecasts, 2021 - 2033
7.3.2. Respiratory Market Estimates and Forecast, By Patient Type 2021 - 2033
7.3.2.1. Neonates
7.3.2.2. Pediatric
7.3.2.3. Adult
7.4. Cardiac
7.4.1. Cardiac Market Revenue Estimates and Forecasts, 2021 - 2033
7.4.2. Cardiac Market Estimates and Forecast, By Patient Type 2021 - 2033
7.4.2.1. Neonates
7.4.2.2. Pediatric
7.4.2.3. Adult
7.5. ECPR
7.5.1. ECPR Market Revenue Estimates and Forecasts, 2021 - 2033
7.5.2. ECPR Market Estimates and Forecast, By Patient Type 2021 - 2033
7.5.2.1. Neonate
7.5.2.2. Pediatric
7.5.2.3. Adult
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.2.1. Vendor Landscape
8.2.2. List of key distributors and channel partners
8.2.3. Key customers
8.2.4. Key company market share analysis, 2024
8.2.5. Inspira
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Abbott
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Terumo Cardiovascular Systems Corporation
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. CytoSorbents Corporation
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Cyberonics, Inc
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. OriGen
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. GOHIBIC™
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Agilent Technologies
8.2.12.1. Company Overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Soma Tech Intl
8.2.13.1. Company Overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. Mott Corporation
8.2.14.1. Company Overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives